

23 June 2016

The Companies Office  
Australian Securities Exchange Limited  
Sydney

---

## Bioxyne Commences New Clinical Trial of its Proprietary Probiotic

Bioxyne Limited (ASX:BXN) today announces that it has signed an agreement with Datapharm Australia to undertake a clinical trial to support its Australian launch and marketing of Progastrim® and proTract®.

The randomized placebo controlled clinical trial is expected to commence in August 2016. The study will examine the effect of Bioxyne's proprietary human-isolated probiotic strain of bacteria to influence the composition of the gut microbiome in healthy adult human volunteers and to examine what gastrointestinal health benefits are associated with daily consumption of the strain in the form of freeze-dried powder in capsules. The strain being tested is *Lactobacillus fermentum* VRI-003, or "PCC®". PCC® has been sold as a dietary supplement in capsule and powder form for over 10 years worldwide with no reported adverse effects.

The effect of PCC® on the composition of the gut microbiome will be quantitatively analysed using kits from Melbourne-based smartDNA Pty Limited.

This technology uses nucleic acid analysis to identify the thousands of species present in the gut of people, and each volunteer's microbiome will be analysed before, during and at the end of the 6 month trial.

"We believe that this is the first time that a probiotic will be tested for its long term effect on the gut microbiome in healthy humans," Dr Peter French, Executive Director and the designer of the trial explained. "PCC® has been demonstrated in previous trials to have beneficial effects on boosting the immune system of elite male athletes and infants, as well as boosting the immune response to the flu vaccine.

Scientific studies have previously shown that PCC® exerts its potent effect on the immune system via the gastrointestinal tract. This study is designed to further confirm that mechanism."

Data from the study will be used to promote the gastrointestinal benefits of Progastrim® in particular.

A second clinical trial, of PCC®'s ability to reduce the symptoms of colds and flu in healthy active adults, is being planned for the next winter season in Australia. That study will build on the positive results from earlier trials of boosting the immune system in elite athletes and in recipients of the flu vaccine, and will be designed to leverage the mechanistic data from the current gastrointestinal trial. The data from the immune trial will be used by our current distributors to promote PCC®'s immune benefits in markets in Europe in particular.

“Bioxyne is committed to demonstrating the clinical efficacy of PCC® to assist in the marketing of its current products as well as new products in new markets,” Bioxyne’s Chairman Mr Tony Ho commented.

“We are pleased to commence an extensive clinical trial program aimed at supporting sales and marketing efforts worldwide.”

## **ENDS**

### **About Bioxyne**

Bioxyne Limited (ASX:BXN) is an Australian life sciences, health and medical technologies company with a focus on immune health and immunotherapeutic products.

Bioxyne has a strategic investment in the consumer dietary supplements and functional foods markets through its proprietary probiotic, *Lactobacillus fermentum* PCC®. Bioxyne is a company creating value for consumers and investors by delivering safe and effective solutions.

Bioxyne’s focus is currently on the company’s probiotic business and proprietary product *Lactobacillus fermentum* PCC® which is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne also has a distribution agreement with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who pride themselves in offering only quality solutions to their customers.

For more information please contact:

**Tony Ho, Non-executive chairman, Bioxyne Limited**

+61 417 345 839

**Jarrold White, Company Secretary | Chief Financial Officer, Bioxyne Limited**

+61 8296 0000